New epilepsy drug SPN-817 put to the test in Year-Long safety study
NCT ID NCT07141329
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the long-term safety and effectiveness of a drug called SPN-817 in adults with focal onset seizures (a type of epilepsy). About 100 people who completed a previous SPN-817 study will take the drug for one year. Researchers will track side effects and measure changes in seizure frequency.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SPN-817 (a drug taken twice daily, starting at a low dose and possibly increasing)
- What this could lead to
- If successful, this could provide a new long-term treatment option to help control focal seizures in adults with epilepsy.
- What could go wrong
- This is an early-phase, open-label extension study with no placebo group, so results may be less reliable. Side effects are possible, and the drug may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL ONSET SEIZURES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medsol Clinical Research Center
RECRUITINGPort Charlotte, Florida, 33952, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.